The move to ease the export ban followed the recommendation of an expert panel led by drug pricing regulator. The panel led by drug pricing regulator Shubhra Singh had been tasked with assessing the capability and the manufacturing capacity of domestic pharmaceutical companies. US had threatened retaliation if ban wasn’t lifted while SAARC, West Asian nations had also sought HCQ.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2RkAGq0
via IFTTT
0 comments:
Post a Comment